Log in
NASDAQ:RDHL

RedHill Biopharma Stock Forecast, Price & News

$8.82
+0.19 (+2.20 %)
(As of 12/4/2020 12:00 AM ET)
Add
Compare
Today's Range
$8.60
Now: $8.82
$8.88
50-Day Range
$7.81
MA: $8.86
$10.36
52-Week Range
$3.26
Now: $8.82
$11.35
Volume105,959 shs
Average Volume353,978 shs
Market Capitalization$329.95 million
P/E RatioN/A
Dividend YieldN/A
Beta1.61
RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focused on gastrointestinal and infectious diseases. The company promotes gastrointestinal drugs, including Movantik for opioid-induced constipation in adults with non-cancer pain; Talicia for the treatment of Helicobacter pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults. Its clinical late-stage investigational development programs include RHB-204, with a planned Phase 3 study for pulmonary nontuberculous mycobacteria infections; opaganib (Yeliva), a SK2 selective inhibitor targeting various indications with a Phase 2/3 program for COVID-19 and Phase 2 studies for prostate cancer and cholangiocarcinoma ongoing; RHB-104, which is in Phase 3 studies for Crohn's disease; RHB-102 (Bekinda) that is in Phase 3 studies for acute gastroenteritis and gastritis, and in Phase 2 studies for irritable bowel syndrome with diarrhea; RHB-107, a Phase 2-stage serine protease inhibitor for cancer and inflammatory gastrointestinal diseases, and is also being evaluated for COVID-19; and RHB-106, an encapsulated bowel preparation. The company was founded in 2009 and is headquartered in Tel Aviv, Israel.
RedHill Biopharma logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.9Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.41 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:RDHL
CUSIPN/A
Phone972-3541-3131
Employees155

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$6.29 million
Book Value$2.74 per share

Profitability

Net Income$-42,300,000.00
Net Margins-219.39%

Miscellaneous

Market Cap$329.95 million
Next Earnings Date3/3/2021 (Estimated)
OptionableOptionable
$8.82
+0.19 (+2.20 %)
(As of 12/4/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive RDHL News and Ratings via Email

Sign-up to receive the latest news and ratings for RDHL and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











RedHill Biopharma (NASDAQ:RDHL) Frequently Asked Questions

How has RedHill Biopharma's stock been impacted by Coronavirus?

RedHill Biopharma's stock was trading at $3.99 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, RDHL shares have increased by 121.1% and is now trading at $8.82.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of RedHill Biopharma?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for RedHill Biopharma in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for RedHill Biopharma
or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than RedHill Biopharma?

Wall Street analysts have given RedHill Biopharma a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but RedHill Biopharma wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is RedHill Biopharma's next earnings date?

RedHill Biopharma is scheduled to release its next quarterly earnings announcement on Wednesday, March 3rd 2021.
View our earnings forecast for RedHill Biopharma
.

How were RedHill Biopharma's earnings last quarter?

RedHill Biopharma Ltd. (NASDAQ:RDHL) issued its earnings results on Tuesday, November, 17th. The biotechnology company reported ($0.50) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.22) by $0.28. RedHill Biopharma had a negative return on equity of 135.90% and a negative net margin of 219.39%.
View RedHill Biopharma's earnings history
.

What price target have analysts set for RDHL?

4 brokers have issued 1-year target prices for RedHill Biopharma's stock. Their forecasts range from $12.00 to $26.00. On average, they anticipate RedHill Biopharma's stock price to reach $18.50 in the next year. This suggests a possible upside of 109.8% from the stock's current price.
View analysts' price targets for RedHill Biopharma
.

Who are some of RedHill Biopharma's key competitors?

What other stocks do shareholders of RedHill Biopharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other RedHill Biopharma investors own include Agenus (AGEN), Sorrento Therapeutics (SRNE), Sangamo Therapeutics (SGMO), Verastem (VSTM), Amarin (AMRN), Aralez Pharmaceuticals (ARLZ), Inovio Pharmaceuticals (INO), Tesla (TSLA), Gilead Sciences (GILD) and NVIDIA (NVDA).

Who are RedHill Biopharma's key executives?

RedHill Biopharma's management team includes the following people:
  • Mr. Dror Ben-Asher, Co-Founder, Chairman & CEO (Age 54, Pay $448.42k)
  • Mr. Micha Ben-Chorin, Chief Financial Officer (Age 51, Pay $339.01k)
  • Mr. Gilead Raday, Chief Operating Officer (Age 45, Pay $361.68k)
  • Mr. Adi Frish, Chief Corp. & Bus. Devel. Officer (Age 50, Pay $338.12k)
  • Mr. Guy Goldberg, Chief Bus. Officer (Age 44, Pay $338.13k)
  • Dr. June S. Almenoff, Chief Scientific Officer (Age 63)
  • Mr. Ben Martie, VP, Legal Affairs
  • Ms. Shani Maurice, VP of Bus. Devel. & Communications
  • Ms. Valerie Graceffa, VP of Sales
  • Mr. Rob Jackson, Sr. VP of Sales & Marketing

What is RedHill Biopharma's stock symbol?

RedHill Biopharma trades on the NASDAQ under the ticker symbol "RDHL."

Who are RedHill Biopharma's major shareholders?

RedHill Biopharma's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Ibex Investors LLC (5.01%), Creative Planning (2.14%), Gagnon Securities LLC (0.64%), Schonfeld Strategic Advisors LLC (0.42%), Wells Fargo & Company MN (0.37%) and ARK Investment Management LLC (0.33%).

Which institutional investors are selling RedHill Biopharma stock?

RDHL stock was sold by a variety of institutional investors in the last quarter, including ARK Investment Management LLC, and Ingalls & Snyder LLC.

Which institutional investors are buying RedHill Biopharma stock?

RDHL stock was purchased by a variety of institutional investors in the last quarter, including Wells Fargo & Company MN, State Street Corp, Schonfeld Strategic Advisors LLC, Colony Group LLC, Gagnon Securities LLC, Creative Planning, Raymond James & Associates, and Morgan Stanley.

How do I buy shares of RedHill Biopharma?

Shares of RDHL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is RedHill Biopharma's stock price today?

One share of RDHL stock can currently be purchased for approximately $8.82.

How big of a company is RedHill Biopharma?

RedHill Biopharma has a market capitalization of $329.95 million and generates $6.29 million in revenue each year. The biotechnology company earns $-42,300,000.00 in net income (profit) each year or ($1.40) on an earnings per share basis. RedHill Biopharma employs 155 workers across the globe.

What is RedHill Biopharma's official website?

The official website for RedHill Biopharma is www.redhillbio.com.

How can I contact RedHill Biopharma?

RedHill Biopharma's mailing address is 21 Ha'arba'a Street, Tel Aviv L3, 64739. The biotechnology company can be reached via phone at 972-3541-3131 or via email at [email protected]

This page was last updated on 12/5/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.